Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Finance»Evexia’s move of acquiring Revin labs, Robust growth forecasted
    Finance

    Evexia’s move of acquiring Revin labs, Robust growth forecasted

    By May 2, 2024No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    In the world of industrial applications, Evexia Lifecare limited stands out as a manufacturer of a range of petrochemical downstream products. These include specialized oils, chemicals, petroleum sulphates, and solvents crucial for industries such as rubber, leather, ink, and paint.

    Going green with eBikes

    A significant milestone was the company’s move into the green energy sector in FY21 with the establishment of an eBike plant in Vadodara. Not just stopping at manufacturing, the company is also gearing up for job work and producing their own line of eBikes.

    Global Financial Moves

    On 3rd February 2023, the company issued 1.50% Listed FCCBs worth USD 1000 Lakhs to the Global Focus Fund from the Republic of Mauritius. This financial move, regulated by the Financial Service Commission of Mauritius, carries a maturity period of 37 months, with an outstanding amount of 68,887.47 Lakhs.

    Diversification and Strategic Acquisitions

    In a bid to diversify the portfolio, the company has delved into trading businesses and commission-based activities, significantly reducing our expenditure. 

    [For more information, visit https://www.evexialifecare.com/ ]

    Moreover, the recent acquisition of REVIN LABS PRIVATE LIMITED, specializing in Analytical Testing Services for Pharmaceuticals, underscores the commitment to growth and innovation. 

    The acquisition, costing 44.8 crores, will be settled with a cash consideration of Rs. 22.4 crores and the issuance of equity shares of Evexia Lifecare Limited to Revin Labs Private Limited’s individual shareholders, at a rate of 140 Rs per share.

    Strategic Partnership for Future Growth

    Our acquisition of an 80% stake in Revin Labs Private Limited is not just about expansion; it is a strategic move to join hands and boost our business forward.

    Navigating Financial Ups and Downs

    While recent financial reports may show some disappointments, our diversified business segments and promising growth opportunities signal robust wealth creation for the company and its investors. 

    This is reflected in our stock’s impressive 50% growth over the past six months, and is currently trading at Rs. 2.53.

    Disclaimer: This highlights the bullishness of stock shares and is not recommended to buy, sell or hold. We have not conducted fundamental or technical analysis and do not have any opinion on the stocks mentioned. Neither the author nor Granium Information Technologies should be held responsible for any damages. Please consult a professional advisor.

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Finance
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments

    November 16, 2026

    Cash Ur Drive Marketing Reports Strong H1 FY27 Performance: EBITDA Rising 13% and Net Profit Growing 8% YoY

    November 16, 2026

    Shyam Dhani Industries Limited Reports H1 FY27 Financial Performance

    November 16, 2026

    Comments are closed.

    Recent Post
    • Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam
    • Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments
    • Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur
    • 8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity
    • Cash Ur Drive Marketing Reports Strong H1 FY27 Performance: EBITDA Rising 13% and Net Profit Growing 8% YoY
    • Shyam Dhani Industries Limited Reports H1 FY27 Financial Performance
    • Apollo Health strengthens its expansion in North India with New Clinic and National Reference Laboratory in Gurugram
    • Merritronix Limited Reports H1 FY27 Results Total Income Up 91%, EBITDA Up 95% and Net Profit Up 224% YoY

    Type above and press Enter to search. Press Esc to cancel.